KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Research & Development (2009 - 2026)

Bristol Myers Squibb (BMY) reported Research & Development of $2.6 billion for Q1 2026, up 17.37% year-over-year from $2.3 billion in Q1 2025, and up 2.44% on a QoQ basis from $2.6 billion in Q4 2025.

Bristol Myers Squibb (BMY) has 18 years of Research & Development data on file, last reported at $2.6 billion in Q1 2026.

  • Quarterly Research & Development rose 17.37% year-over-year to $2.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 billion (down 3.53% YoY) and the FY2025 annual result came in at $10.0 billion, down 10.83% from the prior year.
  • Research & Development climbed to $2.6 billion in Q1 2026 per BMY's latest filing, from $2.6 billion in the prior quarter.
  • Across five years, Research & Development topped out at $3.2 billion in Q4 2024 and bottomed at $2.2 billion in Q3 2023.
  • The 5-year median for Research & Development is $2.5 billion (2023), against an average of $2.5 billion.
  • The widest annual swing landed in 2024, when Research & Development rose 28.77%; it then declined 18.96% in 2025.
  • Tracing BMY's Research & Development over 5 years: stood at $2.5 billion in 2022, then decreased by 1.27% to $2.5 billion in 2023, then climbed by 28.77% to $3.2 billion in 2024, then decreased by 18.96% to $2.6 billion in 2025, then grew by 2.44% to $2.6 billion in 2026.
  • Per Business Quant, the three latest BMY Research & Development figures stand at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.5 billion (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 3.51 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 3.53 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 2.47 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 12.59 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 1.72 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 1.37 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 2.49 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 2.65 Bn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 2.65 Bn
Dec 31, 2025 2.59 Bn
Sep 30, 2025 2.53 Bn
Jun 30, 2025 2.58 Bn
Mar 31, 2025 2.26 Bn
Dec 31, 2024 3.19 Bn
Sep 30, 2024 2.37 Bn
Jun 30, 2024 2.90 Bn
Mar 31, 2024 2.70 Bn
Dec 31, 2023 2.48 Bn
Sep 30, 2023 2.24 Bn
Jun 30, 2023 2.26 Bn
Mar 31, 2023 2.32 Bn
Dec 31, 2022 2.51 Bn
Sep 30, 2022 2.42 Bn
Jun 30, 2022 2.32 Bn
Mar 31, 2022 2.26 Bn
Dec 31, 2021 2.52 Bn
Sep 30, 2021 2.98 Bn
Jun 30, 2021 2.48 Bn
Mar 31, 2021 2.22 Bn
Dec 31, 2020 2.66 Bn
Sep 30, 2020 2.50 Bn
Jun 30, 2020 2.52 Bn
Mar 31, 2020 2.37 Bn
Dec 31, 2019 2.10 Bn
Sep 30, 2019 1.38 Bn
Jun 30, 2019 1.33 Bn
Mar 31, 2019 1.35 Bn
Dec 31, 2018 1.37 Bn
Sep 30, 2018 1.28 Bn
Jun 30, 2018 2.44 Bn
Mar 31, 2018 1.25 Bn
Dec 31, 2017 1.93 Bn
Sep 30, 2017 1.56 Bn
Jun 30, 2017 1.68 Bn
Mar 31, 2017 1.30 Bn
Dec 31, 2016 1.47 Bn
Sep 30, 2016 1.14 Bn
Jun 30, 2016 1.27 Bn
Mar 31, 2016 1.14 Bn
Dec 31, 2015 1.92 Bn
Sep 30, 2015 1.13 Bn
Jun 30, 2015 1.86 Bn
Mar 31, 2015 1.02 Bn
Dec 31, 2014 1.19 Bn
Sep 30, 2014 983.00 Mn
Jun 30, 2014 1.42 Bn
Mar 31, 2014 946.00 Mn
Dec 31, 2013 957.00 Mn
Sep 30, 2013 893.00 Mn
Jun 30, 2013 951.00 Mn
Mar 31, 2013 930.00 Mn
Dec 31, 2012 1.08 Bn
Sep 30, 2012 951.00 Mn
Jun 30, 2012 962.00 Mn
Mar 31, 2012 909.00 Mn
Dec 31, 2011 1.01 Bn
Sep 30, 2011 973.00 Mn
Jun 30, 2011 923.00 Mn
Mar 31, 2011 935.00 Mn
Dec 31, 2010 1.01 Bn
Sep 30, 2010 824.00 Mn
Jun 30, 2010 822.00 Mn
Mar 31, 2010 910.00 Mn
Dec 31, 2009 1.11 Bn
Sep 30, 2009 820.00 Mn
Jun 30, 2009 811.00 Mn
Mar 31, 2009 908.00 Mn